NEWTON, Mass.--(BUSINESS WIRE)--July 18, 2006--Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Dana-Farber/Partners Cancer Care (DFPCC) has enrolled the first patient in a Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients. Michael Seiden, MD, PhD is the Principal Investigator. Dr. Seiden is an Associate Physician in Medicine at Massachusetts General Hospital, Associate Professor of Medicine at Harvard University and oversees the clinical research program and Research Committee for the Gynecologic Cancer Program at the Dana Farber Harvard Cancer Center.
